An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.

Authors

Miaozhen Qiu

Sun Yat-sen University Cancer Center, Guangzhou, China;

Miaozhen Qiu , Hongming Pan , Ka On Lam , Jufeng Wang , Yi Zheng , Huiyan Luo , Yu Zheng , Xiaoa Zhen , Wenzhao Hang , Jianmei Hou , Rui-hua Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

First Author: Igor Tsaur

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase Ⅰ, open-label, multicenter, dose escalation/expansion study.

First Author: Xue Bai

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.

First Author: Anthony W. Tolcher

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.

First Author: Jason J. Luke